DOCSLIB.ORG

Conte Annual Report 2000 / 2001

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Conte Annual Report 2000 / 2001 Coloplast’s Mission Contents Throughout the world we wish to be perceived as depend- Coloplast in brief 2 able providers of consumable products and services. 5 years’ key figures and ratios 3 Our customers are health care professionals and users. Our primary concern is to improve the quality of life of Board and Group Management 4 individuals suffering from a disabling condition. Management report 5 We respond quickly to market needs to ensure the highest level of customer satisfaction. We strive to offer Financial review 11 preferred product ranges based on innovation, advanced technology and cost-effectiveness. Risk factors 15 Accounting policies 17 All employees must be recognised for their empathy with user needs and dependability in business relations. Profit and loss account 19 It is our ambition to attract and retain the best human Balance sheet 20 resources. Consolidated cash flow statement 22 As individuals and as an organisation we will act respon- Auditors’ report and approvals 23 sibly and be socially and environmentally conscious. Notes 24 We strive to be the best within our businesses, thereby achieving growth and value for the company, the em ploy- ees and shareholders. Stakeholder reporting Annual Report 2000 / 2001 – value creation and knowledge management 32 Customers 33 Employees 38 Society 41 Shareholders 43 Indicators for value drivers and value propositions 48 Artist of the year 50 Group addresses Executives Coloplast Mission Coloplast A/S Coloplast, Conveen, Comfeel, Holtedam 1 Amoena, Sween, Compeed, DK-3050 Humlebæk Assura, Easiflex, EasiCath, Coloplast’s Annual Report for 2000/01 has its own Tel. + 45 49 11 11 11 SpeediCath, Biatain, Contreet, microsite on our corporate website at the address: Fax + 45 49 11 15 55 and Prema are registered trade- E-mail: [email protected] marks of the Coloplast Group. www.coloplast.com/annualreport Website: www.coloplast.com Central Registry of Cos. no. 69 74 99 17 Contents Coloplast in brief Coloplast in brief 2 Coloplast was founded in 1957. The company’s shares 5 years’ key figures and ratios 3 were listed at the Copenhagen Stock Exchange in 1983. Coloplast develops, manufactures and markets medical Board and Group Management 4 disposables helping people overcome a physical impair- Management report 5 ment. Based on skin-friendly adhesives, medical devices have been developed within six business areas: • Ostomy products for people whose intestinal outlet Financial review 11 has been surgically rerouted through the abdominal wall Risk factors 15 • Continence care products for people with bladder Accounting policies 17 control problems • Wound dressings for chronic wounds Profit and loss account 19 • Skin care products for prevention and treatment Balance sheet 20 • Breast forms and special textiles for women after breast surgery Consolidated cash flow statement 22 • Special dressings for the consumer products market. Auditors’ report and approvals 23 The market Notes 24 Coloplast is mainly operating in niche markets with few big suppliers. The majority of our products are reim- bursed by health care authorities in the Western World, Stakeholder reporting and generally it is a nurse who chooses the product or – value creation and has an influencing role in its selection. Coloplast has in- knowledge management 32 depth knowledge of the respective countries’ health care Customers 33 systems and is represented by its subsidiaries in most markets. Employees 38 More than 97% of Group turnover is generated Society 41 in countries outside Denmark, including about 76% in Europe and 16% in the USA. Shareholders 43 Coloplast employs 4,203 people worldwide, 2,281 Indicators for value drivers and of them working in Denmark. value propositions 48 Objectives The Group has set an objective of achieving a turnover Artist of the year 50 of DKK 8 bln by the year 2005 and a profit margin of 17%. These objectives can be achieved through organic growth alone. Growth in market shares is anticipated in Group addresses all businesses as a consequence of commercial compe- tences and development of further innovative products Executives and services. Coloplast Mission Coloplast’s Annual Report for 2000/01 has its own microsite on our corporate website at the address: www.coloplast.com/annualreport Coloplast in brief Group addresses Executives at 1 December 2001 PrintDivision A/S Coloplast was founded in 1957. The company’s shares Definitions according to the Danish Society Net turnover and profit margin Denmark Costa Rica Japan Russia In the parent company Coloplast de Costa Rica, S.A. Coloplast K.K. Coloplast A/S were listed at the Copenhagen Stock Exchange in 1983. of Financial Analysts MDKK % Coloplast A/S Printed by Corporate sales Zona Franca Metropolitana YS Building, 4th Floor Usievicha Str., 17 flat 15 Holtedam 1-3 Coloplast develops, manufactures and markets medical 5,000 20 Barreal de Heredia, Heredia 2-11-16 Shiba Daimon Moscow 125315 Jens E. Stovgaard General Manager Employees at year-end is employees converted into full-time DK-3050 Humlebæk Costa Rica, C.A. Minato-ku Russia Michael Jørgsholm General Manager 4,000 16 Tel. +45 49 11 11 11 disposables helping people overcome a physical impair- equivalents Tel. +506 293 3034 Tokyo 105-0012 Tel. + 7095 760 9131 Jesper Jul General Manager E-mail: [email protected] ment. Based on skin-friendly adhesives, medical devices 3,000 12 E-mail: [email protected] Tel. +81 3 34 59 66 41 Fax +7095 151 8064 Jan R. Frederiksen General Manager, Breast Care Review Profit margin Operating profit Bronzevej 2-8 E-mail: [email protected] E-mail: [email protected] have been developed within six business areas: x 100 2,000 8 Denmark Distributor markets Net turnover DK-3060 Espergærde Coloplast Danmark A/S Norway Slovakia Henrik Hjermov General Manager, Export Region 1,000 4 Aa. Louis-Hansens Allé 15 Kokkedal Industripark 2 Coloplast Norge AS Coloplast A/S • Ostomy products for people whose intestinal outlet Return on assets Operating profit Product divisions x 100 0 0 DK-3060 Espergærde 2980 Kokkedal Ole Deviks Vei 2, Etterstad Obchodné Zastupitelstvo Average assets has been surgically rerouted through the abdominal 96 97 98 99 00 Tel. +45 49 11 11 11 0603 Oslo Dolná 62 Svenn Poulsen General Manager, Ostomy Products Division Porthusvej 4 Mogens Pedersen General Manager, Continence Care Division wall 97 98 99 00 01 E-mail: [email protected] Tel. +47 22 72 06 80 974 01 Banská Bystrica Return on capital Operating profit + financial income DK-3490 Kvistgård E-mail: [email protected] Tel. +42 188 415 3761 Sven Lange General Manager, Wound Care Division x 100 Coloplast Konsumentvarer A/S • Continence care products for people with bladder employed Average working capital Net turnover Profit margin E-mail: [email protected] Mogens Wismann Operations Manager, Ostomy Products Division Egevangen 3-4 Egevangen 3E Poland control problems DK-2980 Kokkedal 2980 Kokkedal Coloplast Sp. zo.o. Slovenia Jens K. Pedersen Operations Manager, Continence Care Division Return on average Operating profit Erik Andersen Operations Manager, Wound Care Division Industrivej 7 Tel. +45 49 11 11 11 Ul. Leszno 12 Coloplast A/S • Wound dressings for chronic wounds invested capital Average invested capital DK-7700 Thisted E-mail: [email protected] 01-192 Warszawa Prusnikova 1 Corporate staff + accumulated write-offs of goodwill Tel. +48 22 535 73 73 1210 Ljubljana • Skin care products for prevention and treatment France Merete Brunander International Marketing Manager Operating profit and EPS Coloplast Research E-mail: [email protected] Tel. +386 15 12 7440 Coloplast S.A. Søren Holck General Manager, IT • Breast forms and special textiles for women after Return on equity Adjusted net profit Bakkegårdsvej 406 A E-mail: [email protected] x 100 MDKK. DKK 58, rue Roger Salengro Spain Jens Steen Larsen Corporate Communications Manager breast surgery Average equity DK-3050 Humlebæk 800 20 Tel. +45 49 11 11 11 Peripole 126 Coloplast Productos Médicos S.A. South Africa Bente Laursen Corporate Human Resource Manager • Special dressings for the consumer products market. Net profit adjusted for extraordinary items 94126 Fontenay Sous Bois Cedex Agustin de Foxa 29, 5 Coloplast A/S Peter Samuelsen Corporate Research Manager 600 15 Subsidiaries Tel. +33 1 49 74 17 00 28036 Madrid P.O. Box 505 Peter Volkers Legal Affairs Manager Net asset value Equity at year-end x adjustment factor E-mail: [email protected] Tel. +34 91 314 18 02 Wendywood 2144 Jens Øhrwald Corporate Controller (100% owned unless otherwise E-mail: [email protected] Tel. +27 11 802 2943 The market Number of shares at year-end 400 10 Germany stated) E-mail: [email protected] Coloplast GmbH & Sweden Coloplast is mainly operating in niche markets with few Adjusted for share issues 200 5 In the subsidiaries Argentina Coloplast Beteiligungs GmbH Coloplast AB The Czech Republic Coloplast de Argentina S.A. big suppliers. The majority of our products are reim- Kuehnstrasse 75 Kabelgatan 9 Coloplast A/S Europe Earnings per share Adjusted net profit 0 0 Alicia Moreau de Justo 1780 x 100 22045 Hamburg 434 22 Kungsbacka Kyjovská 1 bursed by health care authorities in the Western World, 96 97 98 99 00 Sigrun Kain Austria, Country Manager Average number of shares 1# piso I - C1107AFJ Buenos Aires Tel. +49 40 66 98 07 -0 Tel. +46 300 332 50 14200 Praha 4 97 98 99 00 01 Eric Bursens Belgium, General Manager and generally it is a nurse who chooses the product or Tel. +54 11 4311 2999 E-mail: [email protected] E-mail: [email protected] Tel. +42 02 444 70212 Adjusted for share issues E-mail: [email protected] Finn Ketler Denmark, General Manager Operating profit EPS E-mail: [email protected] has an influencing role in its selection. Coloplast has in- AMOENA GmbH & Co.
Load more

Recommended publications
  • Aktienyt Novozymes
    Aktienyt Novozymes Hold Udfordrende markeder dæmper salgsvæksten Uændret Hold-anbefaling siden 20/04/2016 Vi fastholder vores Hold-anbefaling på Novozymes Dagens regnskab er lidt svagere, end vi havde ventet. Hård priskonkurrence i ’Bioenergi’ og økonomisk Analysedato: 10/08/2016 pressede kunder i ’Landbrug og Foder’ dæmper Novozymes’ salgsvækst. Pris- fastsættelsen af Novozymes-aktien afspejler efter vores vurdering Novozymes’ Aktuel kurs kl. 12:11: kortsigtede forretningsmuligheder. 295,00 DKK Salgsvæksten skuffer i årets 2. kvartal Omsætningen på 3.429 mio. kr. i 2. kvartal 2016 er 3,3% dårligere end vores estimat (-3,5% i Begivenhed: forhold til markedsforventningen). Resultatet af primær drift på 961 mio. kr. i 2. kvartal 2016 er 2,9% under vores estimat (-2,6% i forhold til markedsforventningen). I forhold til vores for- 2. kvartalsregnskab ventning er det specielt salget i divisionerne ’Bioenergi’ og ’Landbrug og Foder’, der viser en svagere end ventet udvikling i 2. kvartal. Novozymes justerer salgsprognosen for 2016 i lokal Seneste analyse: valuta. Selskabet venter nu en salgsvækst i lokal valuta på 2-4% i 2016 mod tidligere 3-5%. 05/08/16 – Vækst i ’Vaskemid- Novozymes forventer, at salgsvæksten i danske kroner forbliver uændret på 1-3% i 2016. ler’ – Tilbagegang i ’Bioenergi’ Salgsvæksten i ’Vaskemidler’ overgår vores forventning Den organiske salgsvækst i divisionen ’Vaskemidler’ på 4% i 2. kvartal er lidt bedre end vo- res estimat på 3%. Vi hæfter hos ved, at salget vokser i Asien drevet af øget penetration af Kalender: enzymer i flydende vaskemidler. Yderligere noterer vi os, at den positive salgsudvikling er 26/10/16 – 3.
    [Show full text]
  • Novo Nordisk Annual Report 2012
    novo nordisk annual report 2012 Diabetes – an emergency in slow motion Strategy Sustainable growth is all about – can it be done? choice Insulin in Novo Nordisk’s performance in 2012 is a result of important decisions made in recent years a tablet – but there is more to the story – why is it so difficult? Contents Accomplishments and results 2012 1 Letter from the Chairman 2 Letter from the CEO 4 Performance highlights 6 2012 performance and 2013 outlook Our business 15 Strategy is all about choice 20 Diabetes – an emergency Diabetes – an emergency in slow motion 20 in slow motion 22 The protein powerhouse 24 Insulin treatment is a balancing act 26 Insulin in a tablet – why is it so difficult? 28 Simple injections 29 Prevent bleedings 30 Pipeline overview 32 Many markets – one model 38 Sustainable growth – can it be done? 41 With every big opportunity comes a risk Governance, leadership and shares 44 Shares and capital structure The protein 46 Corporate governance 22 powerhouse 49 Remuneration 52 Board of Directors 54 Executive Management Financial, social and environmental statements 55 Consolidated financial, social and environmental statements 104 Financial statements of the parent company 109 Management’s statement and Auditor’s reports Additional information 112 More information Simple 28 injections 113 Product overview The Management review, as defined by the Danish Financial Statements Act (FSA), is found on pp 1–54 and 94. This Annual Report is published in both a Danish and an English language version. In the event of any discrepancies, the Danish version shall prevail. 1 Chairman of the Board of Directors Sten Scheibye at the Annual General Meeting in March 2012.
    [Show full text]
  • Aktiekommentar Novozymes
    Aktiekommentar Novozymes Sælg Novozymes står på dørtærsklen til et kommercielt Uændret gennembrud i 2G-biobrændstofindustrien Aktuel kurs: 216,30 DKK Begivenhed: Vi fastholder Sælg-anbefalingen på Novozymes. Værdiansættelsen af Novozy- mes-aktien indregner efter vores vurdering allerede store forventninger til Novo- zymes’ fremtidige salg og indtjening fra 2G-biobrændstofenzymer. 2G-industrien Optakt til kapitalmar- er dog i sin spæde opstartsfase. Der er fortsat stor usikkerhed forbundet med kedsdag hvilke teknologiske løsninger, der vil blive markedsledende. Vi forventer dog, at Novozymes vil få en betydelig markedsposition som leverandør til 2G-industrien. Baggrund: Novozymes afholder kapitalmarkedsdag den 31. oktober 2013. Det overordnende tema for dagen er anden generations biobrændstof (2G) og mulighederne for Novozymes i denne indu- stri. Verdens første kommercielle 2G-bioethanolproduktion er for nylig startet op i Cresentino i Italien med Novozymes som enzymleverandør. Produktionsanlægget er opført af italienske Beta Renewables, som Novozymes ejer 10% af. Konklusion: På kapitalmarkedsdagen vil vi have fokus på følgende punkter: - Produktionsøkonomien på det italienske 2G-anlæg – er det kommercielt konkurren- cedygtigt? - Statusopdatering på Novozymes’ globale partnerskabsaftaler – tidshorisont for kom- merciel 2G-produktion på forskellige markeder - Novozymes/Beta Renewables styrker i forhold til konkurrerende teknologier Vi forventer, at Novozymes i 2015 kan opnå et globalt enzymsalg til 2G- biobrændstofsproduktion på 213 mio. kr. stigende til 2.166 mio. kr. i 2020. Vi forventer, at Ki- na og Brasilien vil agere vækstmotor for udviklingen af 2G-industrien, mens vi først forventer, at udviklingen i USA kommer op i tempo efter 2015. Det er efter vores vurdering helt centralt, at Novozymes har indgået et samarbejde med itali- enske Beta Renewables.
    [Show full text]
  • Novozymes Continues to Deliver on the Global Goals
    Novozymes continues to deliver on the Global Goals At the UN General Assembly in New York in September 2015, Novozymes joined the rest of the world in welcoming the UN Sustainable Development Goals (SDGs) and the 2030 Agenda for sustainable development. This agenda puts the world on a path toward a more sustainable, viable, low-carbon future, with the SDGs providing a partnership platform for governments, civil society and business to help tackle the world’s challenges. As a global market leader in biological solutions, producing a wide range of industrial enzymes and microorganisms, the intrinsically sustainable nature of Novozymes’ solutions enables us to contribute to one or more of the Sustainable Development Goals (SDGs), directly or indirectly. Every day, we strive to do our part to deliver on the SDGs, from the core of our business and right through our operations. Our contributions are outlined below. In addition, read ‘Working with the SDGs’ in ‘The Novozymes Report 2020’. Embracing our responsibility To shape a future of better business for us, our customers and the world, we need to have a sound, balanced and growing business. This will allow us to continue investing in our leadership position within biotechnology and capture new opportunities in the industries we serve. Our strategy Better business with biology is inspired by the societal needs defined by the Global Goals. Through the strategy, we are committed to developing solutions that can contribute to solving three global challenges: Climate, Water and Production and Consumption. We are also committed to operating our business responsibly and investing to minimize our negative environmental footprint.
    [Show full text]
  • Invitation Annual Shareholders' Meeting 2015
    INVITATION ANNUAL SHAREHOLDERS’ MEETING 2015 To the shareholders of Novozymes A/S The Board of Directors is pleased to invite you to the Company’s Annual Shareholders’ Meeting on WEDNESDAY FEBRUARY 25, 2015 AT 4:00 P.M. at Ballerup Super Arena, Ballerup Idrætsby 4, 2750 Ballerup, Denmark AGENDA: 1. Report on the Company’s activities 5. Election of Chairman The Board of Directors proposes re-election of the 2. Presentation and approval of the audited incumbent Chairman. annual report Henrik Gürtler 3. Resolution on distribution of profit in Born 1953, Chairman, MSc accordance with the approved annual (Engineering), chemical engi- report neer. The Board of Directors re- The Board of Directors proposes a dividend of DKK commends re-election of 3.00 per A/B share of DKK 2 Henrik Gürtler because of his in-depth knowledge of Novozymes’ business, and expertise in managing and 4. Approval of remuneration to members of working in an international biotechnology company. the Board of the Directors for the present Henrik Gürtler serves as chairman of the board of Det year Alm. Danske Ejendomsselskab A/S (DADES A/S). Henrik Gürtler has been a member of the Board of The Board of Directors proposes that the fees for the Directors since 2000. board members and the Audit Committee shall be fixed to: 6. Election of Vice Chairman • The base fee for board members shall be DKK The Board of Directors proposes re-election of the 500,000 incumbent Vice Chairman. • The Chairman of the Board of Directors shall receive 3.0 times the base fee Agnete Raaschou-Nielsen • The Vice Chairman of the Board of Directors shall Born 1957, Chairman of receive 2.0 times the base fee Brdr.
    [Show full text]
  • Aktienyt Novozymes
    Aktienyt Novozymes Hold To cylindre i salgsvækstmotoren sætter ud Uændret Vi fastholder Hold-anbefalingen på Novozymes. Dagens regnskab byder på en Aktuel kurs: overraskende nedjustering af den organiske salgsvækst drevet af udfordringer inden for vaskemidler og bioenergi. Vi forventer ikke, at Novozymes vil være i 321,1 DKK stand til at løse udfordringerne på den korte bane. Begivenhed: Salgsvæksten skuffer markant i 2. kvartal Omsætningen på 3.449 mio. kr. i 2. kvartal 2015 er 5,2 % dårligere end vores estimat (-6,1% 2. kvartalsregnskab ift. markedsforventningerne). Resultatet af primær drift på 930 mio. kr. i 2. kvartal 2015 er 4,7% dårligere, end vi havde forventet (-6,3% ift. markedsforventningerne). Det skal dog bemærkes, at driftsresultatet i 2. kvartal er negativt påvirket af en nedskrivning på 50 mio. kr. Seneste analyse: relateret til Novozymes’ farmaceutiske forretning. Når der ses bort fra nedskrivningen er 17/04/15 – Aktieudsyn – Min- overskudsgraden i 2. kvartal på 28,4%, hvilket er markant over vores estimat på 26,8%. No- dre valuta-drevet nedjustering vozymes nedjusterer salgsprognosen for 2015. Novozymes forventer nu, at salget vil vokse på vej 13-16% i danske kroner i 2015 mod tidligere 16-18%. I lokal valuta forventer Novozymes, at salget vil vokse med 4-7% mod tidligere 7-9%. Den stærke udvikling i indtjeningen i årets første seks måneder betyder, at Novozymes fastholder indtjeningsprognosen for 2015 på trods af den svagere salgsudvikling. Kalender: 22/10/15 – 3. kvartalsregnskab Hård konkurrence bland nordamerikanske vaskemiddelproducenter skaber udfordringer 19/01/16 – Årsregnskab 2015 Omsætningen fra vaskemiddelenzymer er 2% under vores estimat.
    [Show full text]
  • Factsheet | 27 September, 2021 LU0012195615 Marketing Material
    Danske Invest SICAV Denmark Focus Class A Factsheet | 27 September, 2021 LU0012195615 Marketing material Objectives and investment policy Manager Objectives Name: The objective of this fund is to achieve above-market performance. The share Jesper Neergaard Poll class is accumulating. Danske Bank Asset Management Title: Investment policy Chief Portfolio Manager The fund invests mainly in a narrow and focused selection of Danish equities. Background: The fund promotes various environmental and social characteristics and good M.Sc. governance practices through a commitment to systematically identify and Years of experience: address sustainability factors throughout the investment management processes 28 and through active ownership. In actively managing the fund’s portfolio, the management team selects securities that appear to offer superior investment characteristics. 10 largest holdings as of 30.07.2021 *) The fund generally expects that its holdings, and therefore its performance, may not differ significantly from those of the benchmark. Name of investment/security Weight The fund may use derivatives for hedging and efficient portfolio management. Novo Nordisk B 9.9% Recommendation: This fund may not be appropriate for investors who plan to Dsv 8.1% withdraw their money within 5 years. Carlsberg B 6.8% A.P. Møller - Mærsk B 6.8% Ørsted A/S 6.4% Return in the period: 31.08.2016 - 31.08.2021 William Demant Holding A/S 5.1% Coloplast B 5.0% Tryg A/S 4.8% Gn Store Nord 4.5% Pandora 4.1% *) Please note that all holdings are delayed with 1 month. Asset allocation: Sectors as of 30.07.2021, % The default for the chart is the return for the past 5 years as of end of month or, if the fund is less than 5 years old, since launch.
    [Show full text]
  • The Novozymes Report 2017
    The Novozymes Report 2017 Rethink tomorrow Contents The big picture 4 2017 in brief Accounts and performance 15 Letter from the Board of Directors 66 Performance and consolidated financial statements 18 Letter from the CEO 74 Performance and environmental data 21 Novozymes in a nutshell 76 Performance and social & governance data 78 Notes 150 Statements Our business 156 Financial statements for Novozymes A/S 26 Business model 31 Strategy 33 Risk management 38 Targets Governance 49 Corporate governance 54 Board of Directors 57 Executive Leadership Team 59 Remuneration report 63 The Novozymes stock Novozymes A/S 2 The big picture Financial highlights DKK 4% 27.9% Organic sales growth EBIT margin Sales grew by 4% organically and by 3% in DKK. EBIT margin at 27.9% was on par with last year. Sales to Food & Beverages and Bioenergy were Excluding the one-time costs relating to layoffs the most significant contributors to organic in 2017, the cost associated with the change Key figures 2017 2017 sales growth in 2017. to the Executive Leadership Team, and the loss realized outlook* relating to the Albumedix divestment, the EBIT margin was ~29% Sales growth, organic 4% 2-5% Sales growth, DKK 3% 3-6% EBIT growth 3% 3-6% EBIT margin 27.9% ~28% Net profit growth 2% 2-5% Net investments excl. 1,665 1,700- acquisitions, DKKm 1,900 Free cash flow before 2,398 2,000- acquisitions, DKKm 2,200 2% 25.6% ROIC (including goodwill) 25.6% 24-25% Net profit growth ROIC * Outlook guided as of January 18, 2017.
    [Show full text]
  • The Novozymes Report 2019
    The Novozymes Report 2019 Where we make a difference In 2019, an estimated 5.9 billion people used products made with our solutions on a weekly basis Rethink tomorrow Novozymes A/S 1 Our purpose Contents Together we find biological answers for better lives in a growing world – Let's rethink tomorrow The big picture Accounts and performance 4 2019 in brief 52 Performance and consolidated 2019 in brief 14 Five-year summary financial statements 2019 was a challenging year for 15 Letter from the Board of 60 Performance and 48% Novozymes. Several industries Directors environmental data experienced strong headwinds Novozymes holds an but there were signs of recovery in 17 Letter from the CEO 62 Performance and social estimated 48% share of Household Care. 19 This is Novozymes & governance data the global enzyme market. 21 Novozymes and the Sustainable 64 Notes Development Goals 136 Statements 142 Financial statements for Strategy Our business Novozymes A/S Novozymes’ updated strategy Better 24 Strategy 157 Glossary business with biology was launched in 29 Risk management 158 About the report June 2019. It will help us capture the right opportunities at the right time 33 Targets together with our customers. 34 Outlook for 2020 Governance 37 Corporate governance Explore 40 Board of Directors the highlights of the 42 Executive Leadership Team Novozymes Report 2019 at report2019.novozymes.com 44 Remuneration report 49 The Novozymes stock Novozymes A/S 2 4 2019 in brief 14 Five-year summary 15 Letter from the Board of Directors 17 Letter from the CEO 19 This is Novozymes 21 Novozymes and the Sustainable Development Goals Where we make a difference Novozymes’ solutions contributed to an estimated saving of 87 million tons CO 2 for our customers in 2019 The big picture Financial highlights 2019 2019 Key figures realized outlook1 DKK Sales growth, organic (1)% (2)-0% EBIT margin 28.1% 27-28% Net profit growth (2)% (5)-0% 28.1% -1% -2% Net investments excl.
    [Show full text]
  • ENGLISH JOB DENMARK Recruitment Announcements Part of the Welcome Group
    ENGLISH JOB DENMARK Recruitment Announcements Part of The Welcome Group MARKETING CREATION AND CREATE THE FUTURE: UK NATIVE SPEAKER PRODUCTION COORDINATOR, INNOVATION PROJECT BUSINESS DEVELOPMENT GN GROUP MANAGER (14327), DEMANT REPRESENTATIVES - PART TIME, If you are a born project coordinator, You will work on high-uncertainty CLERK.IO digital native and have experience technologies, ideas and concepts that have We are seeking the next generation of from the agency side, if you enjoy and the potential to significantly impact hearing ambitious sales and marketing professional excel at managing several creative and healthcare. superstars who are looking to develop their complex processes at the same time and Location: Smørum skills across technical selling, demand want to join an organization with lots of Deadline: 30 November 2020 generation, sales operations, networking opportunities to grow and develop your and negotiations. career, you should apply for this role. Contact: Thor Højlund Olsen, Location: Copenhagen Location: Ballerup Director, Discovery, [email protected] Deadline: Casting on 18 November 2020 Deadline: 23 November 2020 Contact: +45 70 55 51 00 Contact: Mette Gramkow, Team lead, +45 24 76 91 59 JAVASCRIPT TECHNICAL EVANGELIST, SITECORE RESEARCH SCIENTIST, A Technical Evangelist uses deep NOVOZYMES PEOPLE ANALYTICS LEAD, development knowledge, engaging Do you want to rethink your impact, and are HEMPEL technical writing and persuasive you passionate about application science? A newly established position as our People presentation skills to show the endless Then you might be our new agile research Analytics Lead to help us become more possibilities of creating unique experiences scientist. data-driven, and help shape improved with Sitecore.
    [Show full text]
  • Important Notice the Depository Trust Company
    Important Notice The Depository Trust Company B #: 3489-16 Date: June 20, 2016 To: All Participants Category: Dividends From: International Services Attention: Operations, Reorg & Dividend Managers, Partners & Cashiers DENMARK ADR MARKET ANNOUNCEMENT ISSUE CUSIP A.P. MOLLER - MAERSK 00202F102 CARLSBERG 142795202 CHR. HANSEN 12545M207 COLOPLAST A/S 19624Y101 Subject: DSV 26251A108 FLSMIDTH & CO A/S 343793105 GN STORE NORD 3621ME105 NOVOZYMES A/S 670108109 PANDORA 698341104 SYDBANK 87124G102 VESTAS WIND SYSTEMS A/S 925458101 Effective as of September 13, 2016 Participants can use DTC’s Corporate Actions Web (CA Web) service to certify all or a portion of their position entitled to the applicable withholding tax rate. Participants are urged to consult TaxInfo respectively before certifying their instructions over the CA Web. Important: Prior to certifying tax withholding instructions, participants are urged to read, understand and comply with the information in the Legal Conditions category found on TaxInfo on the CA Web. Questions regarding this Important Notice may be directed to GlobeTax 212-747-9100. DTCC offers enhanced access to all important notices via a Web-based subscription service. The notification system leverages RSS Newsfeeds, providing significant benefits including real-time updates and customizable delivery. To learn more and to set up your own DTCC RSS alerts, visit http://www.dtcc.com/subscription_form.php. Non-Confidential 1 DTCC Public (White) Important Legal Information: The Depository Trust Company (“DTC”) does not represent or warrant the accuracy, adequacy, timeliness, completeness or fitness for any particular purpose of the information contained in this communication, which is based in part on information obtained from third parties and not independently verified by DTC and which is provided as is.
    [Show full text]
  • A.P. Møller - Mærsk A/S
    A.P. Møller - Mærsk A/S Annual Report 2016 Esplanaden 50, DK-1098 Copenhagen K / Registration no. 22756214 A.P. Moller - Maersk — Annual Report 2016 CONTENTS DIRECTORS’ REPORT FINANCIALS ADDITIONAL INFORMATION Highlights Consolidated financial Board of Directors 1 statements 2016 Guidance for 2017 Management Board 1 Parent company financial Five year summary statements 2016 Company overview 2 Strategy Statement of the Board of Directors Definition of terms Invested capital and ROIC and the Management Board Company announcements 2016 Financial review of the businesses Independent Auditor’s Report External financial reporting for A.P. Moller - Maersk1 Financial report PAGES 35-104 PAGES 105-115 Q4 2016 financials Risk management Corporate governance Shareholder information PAGES 3-34 The Annual Report for 2016 of A.P. Møller - Mærsk A/S (further referred to as A.P. Moller - Maersk as the consolidated group of companies and A.P. Møller - Mærsk A/S as the parent company) has been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU and further requirements in the Danish Financial Statements Act. Comparative figures Unless otherwise stated, all figures in parenthesis refer to the 1 Part of Directors’ Report corresponding figures for the previous year. 2 Part of Financials 2 / 115 A.P. Moller - Maersk — Annual Report 2016 Contents Directors’ report Highlights / Guidance for 2017 / Five year summary / Strategy / Invested capital and ROIC / Financial review of the businesses / Financial report / Q4 2016 financials Risk management / Corporate governance / Shareholder information / Board of Directors / Management Board / External financial reporting for A.P. Moller - Maersk 3 / 115 A.P.
    [Show full text]